Trial · NCT04233918
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part A: Maximum Observed Serum Concentration (Cmax) of Evinacumab | Part A: Evinacumab 15mg/Kg IV | 238 | Standard Deviation 90.8 | Milligrams per Liter (mg/L) | |
| Part A: Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) of Evinacumab | Part A: Evinacumab 15mg/Kg IV | 4576 | Standard Deviation 1568 | Days*Milligrams per Liter (day*mg/L) | |
| Part A: Terminal Half-Life (t1/2) of Evinacumab | Part A: Evinacumab 15mg/Kg IV | 7.69 | Full Range 6.18 to 12.4 | Days | |
| Part B: Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 | Part B: Evinacumab 15mg/Kg IV Q4W | -48.3 | 95% Confidence Interval -68.8 to -27.8 | Percentage of Change | |
| Part A and Part B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Part A: Evinacumab 15mg/Kg IV | 5 | Participants | ||
| Part A and Part B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Part B: Evinacumab 15mg/Kg IV Q4W | 10 | Participants | ||
| Part B: Percent Change in Apolipoprotein B (Apo B) From Baseline to Week 24 | Part B: Evinacumab 15mg/Kg IV Q4W | -41.3 | 95% Confidence Interval -58.9 to -23.8 | Percentage of Change | |
| Part B: Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 24 | Part B: Evinacumab 15mg/Kg IV Q4W | -48.9 | 95% Confidence Interval -68.1 to -29.7 | Percentage of Change | |
| Part B: Percent Change in Total Cholesterol (TC) From Baseline to Week 24 | Part B: Evinacumab 15mg/Kg IV Q4W | -49.1 | 95% Confidence Interval -64.9 to -33.2 | Percentage of Change | |
| Part B: Percentage of Participants With ≥50 Percent (%) Reduction in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 | Part B: Evinacumab 15mg/Kg IV Q4W | 78.6 | Percentage of Participants | ||
| Part B: Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 in Participants Who Have Negative/Negative and Null/Null Mutations | Part B: Evinacumab 15mg/Kg IV Q4W | Negative/negative mutations | -67.7 | Standard Error 6.5 | Percentage of Change |
| Part B: Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 in Participants Who Have Negative/Negative and Null/Null Mutations | Part B: Evinacumab 15mg/Kg IV Q4W | Null/Null mutations | -57.2 | Percentage of Change | |
| Part B: Percent Change in Lipoprotein A (Lp[a]) From Baseline to Week 24 | Part B: Evinacumab 15mg/Kg IV Q4W | -37.3 | 95% Confidence Interval -42.2 to -32.3 | Percentage of Change | |
| Part B: Absolute Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Week 24 | Part B: Evinacumab 15mg/Kg IV Q4W | -131.9 | Standard Error 30.0 | Milligrams per Deciliter (mg/dL) | |
| Part B: Serum Concentration of Total Evinacumab | Part B: Evinacumab 15mg/Kg IV Q4W | Week 0 | 0 | Standard Deviation 0 | Milligrams per Liter (mg/L) |
| Part B: Serum Concentration of Total Evinacumab | Part B: Evinacumab 15mg/Kg IV Q4W | Week 0.006 | 256 | Standard Deviation 58.0 | Milligrams per Liter (mg/L) |
| Part B: Serum Concentration of Total Evinacumab | Part B: Evinacumab 15mg/Kg IV Q4W | Week 4 | 62.6 | Standard Deviation 22.6 | Milligrams per Liter (mg/L) |
| Part B: Serum Concentration of Total Evinacumab | Part B: Evinacumab 15mg/Kg IV Q4W | Week 4.006 | 293 | Standard Deviation 92.3 | Milligrams per Liter (mg/L) |
| Part B: Serum Concentration of Total Evinacumab | Part B: Evinacumab 15mg/Kg IV Q4W | Week 8 | 98.8 | Standard Deviation 37.7 | Milligrams per Liter (mg/L) |
| Part B: Serum Concentration of Total Evinacumab | Part B: Evinacumab 15mg/Kg IV Q4W | Week 8.006 | 356 | Standard Deviation 76 | Milligrams per Liter (mg/L) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04233918/results